Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
May 28, 2025
Foley Viewpoints
U.S. and International Antitrust Agencies Signal Aggressive Antitrust Enforcement in Procurement, Consumer Products, and Labor Markets
As we previously reported on April 15 and April 28, the Department of Justice (DOJ) and Federal Trade Commission (FTC) are increasingly…
May 28, 2025
Foley Career Perspectives
Foley AANHPI Heritage Month Program: A Conversation With Crypto Journalist Laura Shin
In celebration of Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month, Foley & Lardner hosted a firmwide…
June 7, 2025
Events
HCCA Orange County Regional Healthcare Compliance Conference
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking at the Health Care Compliance Association’s Orange County Regional Healthcare Compliance Conference on June 7.